Deutsche Bank Ag\ Equillium, Inc. Transaction History

Deutsche Bank Ag\

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.56 - $1.24 $4,704 - $10,416	-8,400 Reduced 2.36%	348,061 $254,000
Q2 2021 Aug 11, 2021	BUY	$5.11 - $7.64 $33,015 - $49,362	6,461 Added 1.85%	356,461 $2.1 Million
Q1 2021 May 13, 2021	BUY	$5.03 - $10.5 $1.76 Million - $3.68 Million	350,000 New	350,000 $2.5 Million
Q1 2020 May 14, 2020	SELL	$2.3 - $5.5 $2,300 - $5,500	-1,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.0 - $5.0 $3,000 - $5,000	1,000 New	1,000 $3,000
Q3 2019 Nov 14, 2019	SELL	$3.31 - $5.6 $4,352 - $7,363	-1,315 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$5.28 - $8.2 $28,079 - $43,607	-5,318 Reduced 80.17%	1,315 $7,000
Q1 2019 May 15, 2019	SELL	$5.84 - $12.02 $1,308 - $2,692	-224 Reduced 3.27%	6,633 $52,000
Q4 2018 Feb 14, 2019	BUY	$6.32 - $19.44 $43,336 - $133,300	6,857 New	6,857 $54,000

11.5M

38.1K

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $29.5M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.